Patent US4753793A successfully refreshed from Google Patents.
US4020162A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oxytetracycline solution for parenteral, peroral and local administration and processes for the production thereof
Assignee: Novartis Corp
•
Filing: 1975-02-07
•
Granted: 1977-04-26
•
Expires: 1995-02-07
Abstract
Abstract The present invention relates to an aqueous oxytetracycline solution for parenteral, peroral and local administration, which contains, in addition to the active substance present as base or as salt, polyethylene glycol having a mean molecular weight of 300 to 600, a soluble magnesium salt, a base, preservatives and a buffer system, and to a process for producing this solution.
Inventors
- 👤 Hans Peter Ghilardi
- 👤 Kaya Atasoy
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 15:48
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K31/00; A61K31/65; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/16; A61K47/18
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
91 words
A process for the production of oxytetracycline solutions which comprises suspending 4-11% oxytetracycline in the form of the free base or the hydrochloride salt in 18-28% polyethylene glycol having a mean molecular weight of about 300 to 600, and thereafter admixing therewith in the presence of a nitrogen gas stream, 2.5-5.5% magnesium chloride, 1.3-4.3% of a base, 0.4-0.5% of a preservative, tris-(hydroxymethyl)-aminomethane-hydrochloride in a total concentration of 0.1-0.35% amino methane and 2.0-8.5% 0.1N HCl and 40-80%, by weight, of water; said concentration being based on the weight of the total solution.
Claim 2
Dependent Claim
91 words
A process for the production of oxytetracycline solutions which comprises suspending 4-11% oxytetracycline in the form of the free base or the hydrochloride salt in 18-28% polyethylene glycol having a mean molecular weight of about 300 to 600, and thereafter admixing therewith in the presence of a nitrogen gas stream, 2.5-5.5% magnesium chloride, 1.3-4.3% of a base, 0.4-0.5% of a preservative, tris-(hydroxymethyl)-aminomethane-hydrochloride in a total concentration of 0.1-0.35% amino methane and 2.0-8.5% 0.1N HCl and 40-80%, by weight, of water; said concentration being based on the weight of the total solution.
Claim 3
Dependent Claim
84 words
An aqueous oxytetracycline solution for parenteral, peroral and local administration, which comprises, 4-11% of oxytetracycline in the form of the free base or the hydrochloride salt, 2.5-5.5% of magnesium chloride, 18-28% of polyethylene glycol having a mean molecular weight of about 300 to 600, 1.3-4.3% of a base, 0.4-0.5% of a preservative for said solution, tris-(hydroxymethyl)-aminomethane-hydrochloride in a total concentration of 0.1-0.35% aminomethane and 2.0%-8.5% 0.1N HCl, and 40 to 80% of water; said concentrations being based on the weight of the total solution.
Claim 4
Dependent Claim
84 words
An aqueous oxytetracycline solution for parenteral, peroral and local administration, which comprises, 4-11% of oxytetracycline in the form of the free base or the hydrochloride salt, 2.5-5.5% of magnesium chloride, 18-28% of polyethylene glycol having a mean molecular weight of about 300 to 600, 1.3-4.3% of a base, 0.4-0.5% of a preservative for said solution, tris-(hydroxymethyl)-aminomethane-hydrochloride in a total concentration of 0.1-0.35% aminomethane and 2.0%-8.5% 0.1N HCl, and 40 to 80% of water; said concentrations being based on the weight of the total solution.
Claim 5
Dependent Claim
19 words
Oxytetracycline solution according to claim 2, characterised in that the polyethylene glycol has a mean molecular weight of 400.
Claim 6
Dependent Claim
19 words
Oxytetracycline solution according to claim 2, characterised in that the pH-value of the solution is between 8.0 and 9.0.
Claim 7
Dependent Claim
19 words
Oxytetracycline solution according to claim 4, characterised in that the pH-value of the solution is between 8.5 and 8.9.
Claim 8
Dependent Claim
21 words
Oxytetracycline solution according to claim 2, characterised in that the molecular ratio of oxytetracycline to magnesium chloride is 1:1 to 1:4.
Claim 9
Dependent Claim
18 words
Process according to claim 1, characterised in that the polyethylene glycol has a mean molecular weight of 400.
References Cited (Backward Citations)
US2699054A
Cited
US3017323A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-04-25 | 1980-10-25 | 1981-04-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-04-25 | 1984-10-25 | 1985-04-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-04-25 | 1988-10-25 | 1989-04-26 | $7700.00 | Window Closed / Lapsed |